The high price for new hepatitis drugs has drawn attention and experts say the key to determining whether treatments are worth the cost is the rate of sustained virologic response. Researcher Andrea Branch at Mount Sinai Hospital in New York City is monitoring the new drugs and may have some answers later this year, but she says for hepatitis C patients a cure can be priceless. University of Chicago Medical Center's Nancy Reau says the bottom line is more simple: "People with hep C cost money."

Related Summaries